Clinical and laboratory changes induced by alpha interferon in XXXX --a pilot study.

@entity1 @entity6491 @entity1072 @entity3027
Ten @entity1072 @entity1 were treated with partially pure alpha interferon ( @entity3027 ) at doses ranging from 3-9 X 10(6) units administered intramuscularly daily. Of these @entity1 , three @entity1 with disease stages 0, 1, and 3 (and @entity6491 ), respectively, responded with partial remissions lasting from 10 to 24+ months; four additional @entity1 had minor responses. Among those responding, modulation of @entity1072 , surface immunoglobulins, and surface antigens were observed in four @entity1 . These changes included a decline in the proportion of B cells bearing surface immunoglobulin without change in the number of the B cells. Likewise, a decline in the proportion of B cells bearing T-1 antigen was observed in three @entity1 . Increase in the percentage of T cells, primarily the T helper cells, was seen in two of the responding @entity1 . Specific binding of alpha interferon was demonstrated prior to therapy in @entity1072 cells of all @entity1 . This binding declined rapidly following treatment with @entity3027 . Induction of the enzyme 2'5' oligoisoadenylate synthetase was examined in @entity1072 @entity1 prior to and during therapy with @entity3027 . Variable levels of the enzyme were induced in all @entity1 on therapy; however, only minimal induction was observed in two of three @entity1 failing therapy.
